Biogen (BIIB)
(Delayed Data from NSDQ)
$144.87 USD
+1.19 (0.83%)
Updated Sep 17, 2025 04:00 PM ET
After-Market: $145.63 +0.76 (0.52%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth D Momentum C VGM
Fundamental Charts
About Market Cap
As of the previous market close, Biogen Inc. has a market cap of $21.07B, which represents its share price of $143.68 multiplied by its outstanding shares number of 146.62M. As a large-cap company, BIIB's shareholders are generally exposed to less risk than shareholders of small and mid-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
BIIB 144.87 +1.19(0.83%)
Will BIIB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BIIB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BIIB
Will AbbVie's Neuroscience Portfolio Continue to Aid Top-line Growth?
IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride
BIIB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales
Biogen Secures FDA Nod for Subcutaneous Maintenance Dosing of Leqembi
DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26
Other News for BIIB
Pocket Pivot appears for BIIB after 0.25% move
Biogen (BIIB) Gains EU Approval for Post-Partum Depression Treatment
Biogen (BIIB) Receives E.U. Approval for ZURZUVAE in Treating Postpartum Depression
Biogen gets EU nod for Zurzuvae to treat post-partum depression
Biogen receives EC approval for Zurzuvae